Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity

Human Cell

Volumn 24, Issue 2, 2011, Pages 65-73

  Yasue, Akira ^a   Hasegawa, Kiyoshi ^a   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endometrial carcinoma; k ras; MSI; p53; PTEN; Tamoxifen

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PTEN PHOSPHOHYDROLASE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958039873     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-010-0005-9     Document Type: Article

References (39)

1. Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-88.
2. Tamoxifen. IARC Monogr Eval Carcinog Risks Hum. 1996; 66: 253-365.
3. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchow Arch. 2004; 444: 213-23.
4. Matias-Guin X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001; 32: 569-77.
5. Enomoto T, Fujita M, Inoue M, et al. Alteration of the p53 tumor suppressor gene and its association with activation of the c-k-ras protooncogene in premalignant and malignant lesions of the human endometrium. Cancer Res. 1994; 53: 1883-8.
6. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000; 88: 814-24.
7. Lynch HT, Casey MJ, Shaw TG. Hereditary factors in gynecologic cancer. Oncologist. 1998; 3: 319-38.
8. Peltomaki P, Vasen H. Mutations associated with HNPCC/INSiGHT mutation database. Dis Markers. 2004; 20: 269-76.
9. Vasen HF, Watson P, Mecklin JP. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116: 1453-6.
10. Nassif NT, Lobo GP, Wu X, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene. 2004; 23: 617-28.
11. Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res. 2001; 61: 4545-9.
12. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-57.
13. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66: 7810-7.
14. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 1985; 69: 237-8.
15. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351: 1451-67.
16. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989; 1: 117-20.
17. Elwood JM, Boyes DA. Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of oestrogens. Gynecol Oncol. 1980; 10: 173-87.
18. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994; 55: 164-8.
19. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527-37.
20. Hachisuga T, Saito T, Kigawa J, et al. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers. Gynecol Oncology. 2004; 95: 139-44.
21. Sagawa T, Yamada H, Yamamoto R, et al. Two cases of endometrial cancer meeting new clinical criteria of hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2000; 79: 327-31.
22. Soliman PT, Broaddus RR, Schmeler KM, et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005; 20: 9344-50.
23. Yoon SN, Ku JL, Shin YK, et al. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int J Cancer. 2008; 122: 1077-81.
24. Ichikawa Y, Lemon SJ, Wang S, et al. Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet. 1999; 112: 2-8.
25. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993; 71: 677-85.
26. Takano K, Ichikawa Y, Ueno E, et al. Microsatellite instability and expression of mismatch repair genes in sporadic endometrial cancer coexisting with colorectal or breast cancer. Oncol Rep. 2005; 13: 11-6.
27. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57: 3935-40.
28. Holtz D, Ramondetta LM, Burke TW, et al. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002; 22: 2945-8.
29. Fujimoto I, Shimizu Y, Hirai Y, et al. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol. 1993; 48: 196-202.
30. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993; 53: 1906-10.
31. Barakat RR. Tamoxifen and endometrium. Cancer Treat Res. 1998; 94: 196-207.
32. Hachisuga T, Miyakawa T, Tsujioka H, et al. K-ras mutation in tamoxifen-related endometrial polyps. Cancer. 2003; 98: 1890-7.
33. Kim SY, Suzuki N, Laxmi YR, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev. 2004; 36: 199-218.
34. Kuwashima Y, Kurosumi M, Kobayashi Y, et al. Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int J Gynecol Pathol. 1998; 17: 135-9.
35. Prasad M, Wang H, Douglas W, et al. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol. 2005; 96: 25-31.
36. Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000; 356: 881-7.
37. Fujiwara K, Enomoto T, Fujita M, et al. Alterations of the K-ras and p53 genes in tamoxifen-associated endometrial carcinoma. Oncol Rep. 2008; 19: 1293-8.
38. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995; 26: 1268-74.
39. Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003; 17: 2352-60.